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Background: Numerous studies have demonstrated that autophagy plays a vital role in maintaining cellular
homeostasis. Interestingly, several anticancer agents were found to exert their anticancer effects by triggering
autophagy. Emerging data suggest that autophagy represents a novel mechanism that can be exploited for
therapeutic benefit. Pharmacologically active natural compounds such as those from marine, terrestrial plants and
animals represent a promising resource for novel anticancer drugs. There are several prominent examples from
the past proving the success of natural products and derivatives exhibiting anticancer activity. Helenalin, a
sesquiterpene lactone has been demonstrated to have potent anti-inflammatory and antitumor activity. Albeit
previous studies demonstrating helenalin’s multi modal action on cellular proliferative and apoptosis, the
mechanisms underlying its action are largely unexplained.
Methods: To deduce the mechanistic action of helenalin, cancer cells were treated with the drug at various
concentrations and time intervals. Using western blot, FACS analysis, overexpression and knockdown studies,
cellular signaling pathways were interrogated focusing on apoptosis and autophagy markers.
Results: We show here that helenalin induces sub-G1 arrest, apoptosis, caspase cleavage and increases the levels
of the autophagic markers. Suppression of caspase cleavage by the pan caspase inhibitor, Z-VAD-fmk, suppressed
induction of LC3-B and Atg12 and reduced autophagic cell death, indicating caspase activity was essential for
autophagic cell death induced by helenalin. Additionally, helenalin suppressed NF-κB p65 expression in a dose
and time dependent manner. Exogenous overexpression of p65 was accompanied by reduced levels of cell death
whereas siRNA mediated suppression led to augmented levels of caspase cleavage, autophagic cell death markers
and increased cell death.
Conclusions: Taken together, these results show that helenalin mediated autophagic cell death entails inhibition of
NF-κB p65, thus providing a promising approach for the treatment of cancers with aberrant activation of the NF-κB
pathway.
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The efforts of many researchers during the past dozen
years to identify novel compounds with anticancer activ-
ity have pointed to plants and herbs used in herbal
medicine. The rationale behind this approach is that
herbal medicine looks back on a 5000-years tradition.
Hence, it can be expected that many medicinal herbs
and plants have been selected for pharmacological activ-
ity [1]. Many studies have shown that herbal medicine is
indeed a valuable resource for novel compounds with ac-
tivity against tumors in vitro and in vivo [2-4]. Hence,
the chances to find novel compounds with activity
against tumor cells in natural product libraries are
higher than in synthetic libraries.
In this regard, helenalin, a naturally occurring ses-
quiterpene lactone has generally been considered as a
distinctly promising and potent antitumor compound.
Helenalin has been shown to be a potent inhibitor of
hTERT (human Telomerase Reverse Transcriptase) and
telomerase in hematopoietic cancer cell [5], induces
apoptosis in activated CD4+ T cells through the mito-
chondrial apoptosis pathway [6] and have been shown to
selectively alkylate the p65 subunit of NF-κB [7].
In this report, we provide a mechanism by which
NF-κB p65 plays a significant role in modulating auto-
phagy induced cell death by the sesquiterpene lactone,
helenalin. NF-κB p65 expression is down regulated upon
helenalin treatment in a time and dose dependent man-
ner. Down regulation of NF-κB p65 in turn induces cas-
pase cleavage and autophagic genes Atg12 and LC3-B
resulting in sub-G1 arrest and cell death. Exogenous ex-
pression of NF-κB p65 attenuates caspase cleavage and
subsequently autophagy, demonstrating a mechanistic path-
way of helenalin induced autophagic cell death. siRNA
mediated transcriptional knockdown of NF-κB p65, Atg12
or LC3-B or inhibition of caspase cleavage using Z-VAD-
fmk diminishes autophage cell death. In addition, helena-
lin induced apoptosis by activating the intrinsic apoptosis
pathway. Taken together, we surmise that helenalin
mediated apoptotic and autophagic cell death may pro-
vide a promising treatment strategy for cancers with ab-
errant activation of the NF-kB pathway.
Methods
Cell Culture and drug treatment
A2780 (human ovarian cancer cell line), RKO (colon car-
cinoma cancer cell line) and MCF-7 (breast adenocar-
cinoma cancer cell line) were obtained from ATCC
(Manassas, VA). Cells were cultured in Dulbecco’s modi-
fied Eagle’s medium, supplemented with 10 % fetal bo-
vine serum, 1 % penicillin-streptomycin (all from GIBCOW
Invitrogen, Carlsbad, CA) in a humidified 5 % CO2 atm
at 37 °C. Cells were treated with helenalin (Ambrosa-2,11
(13)-dien-12-oic acid, 6-α,8-β-dihydroxy-4-oxo-, 12,8-lactone) purchased from EMD biosciences (Gibbstown,
NJ). Dimethyl sulfoxide was used throughout the experi-
ments as the vehicle control. At least three biological
experiments were performed to verify observations.
Flow cytometry analysis
Cells were harvested after drug treatment and fixed with
70 % ethanol. Fixed cells were treated with RNase
(100 μg/ml) and stained with propidium iodide (50 μg/ml).
Subsequently, stained cells were analyzed for DNA con-
tent by flow cytometry using FACScalibur (Becton Dickinson,
Franklin Lakes, NJ). Cell cycle fractions were quantifies
using the CellQuest software (BD Biosciences, San Jose,
CA). Further details can be found in [8]. At least three bio-
logical experiments were performed to verify observations.
Cell Proliferation Assay
Inhibition of cell proliferation by helenalin was assessed
using the MTT assay (Roche, Indianapolis, IN). Briefly,
A2780, MCF-7 or RKO cells were plated in 96-well cul-
ture plates (5 × 104 cells/well) and treated the following
day with helenalin or DMSO vehicle as described in the
results section. Following helenalin treatment, cells were
incubated with MTT labeling reagent for 4 h, solubilized
in 10 % SDS, and the MTT metabolite formazan crystals
were quantitated at 575 nm on a microplate reader (Tecan,
Männedorf, Switzerland). All experiments were performed
and verified using at least three biological replicates.
Clonogenic Assay
To determine the growth suppression effect of helenalin
treatment, A2780 cells were treated with helenalin or
DMSO vehicle for 24 h. After treatment, cells were replated
in complete DMEM and allowed to grow for 14 days to
form colonies that were then stained with crystal violet
(Sigma) and quantified. All experiments were performed
and verified using at least three biological replicates.
Annexin-V measurements
Direct fluorescence staining of apoptotic cells for flow
cytometric analysis was performed with the Annexin
V-FITC apoptosis detection kit (BD Pharmingen, San
Jose, CA). After the indicated times, cells were harvested
and stained according to the manufacturer’s protocol.
Stained cells were analyzed in a flow cytometer. All
experiments were performed and verified using at least
three biological replicates.
Western Blotting
Western blotting procedure was followed according to
[8]. Briefly, cells were lysed in appropriate volume of
lysis buffer (Sigma Aldrich, St. Louis, MO). 50 μg of pro-
tein samples were separated by SDS-PAGE and trans-
ferred onto nitrocellulose membrane (Bio-Rad, Hercules,
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antibodies purchased from Cell Signal Technology
(Danvers, MA) or Santa Cruz Biotechnology, Inc (Santa
Cruz, CA). Blots were incubated with horseradish peroxide-
conjugated goat anti-rabbit, goat anti mouse or rabbit
anti-goat secondary antibodies purchased from Santa
Cruz Biotechnology, Santa Cruz, CA. All experiments
were performed and verified using at least three bio-
logical replicates.
siRNA transfection
A2780 cells were transfected with non-targeting control
siRNA (siRNA Neg), siRNA Atg12, siRNA LC3-B or
siRNA RelA p65 when cells reached 80 % confluency.
After 24 h, cells were split 1:3, and treated with helenalin
or DMSO the next day. Final siRNA concentration
was 100nM and transfection was performed using Lipo-
fectamine RNAimax (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s protocol. Target sequences
used for siRNA against Atg12, LC3-B and RelA p65
were 5′CUUAACAGAUGUGAUCUAU-3′, 5′-GUAAU
UCCAGCAGUAAUUU-3′, 5′-CUCAAGAUCUGCCGA
GUGA-3′ respectively. All experiments were performed
and verified using at least three biological replicates.
Plasmid transfection
A2780 cells were transfected with 2.0 ug of empty vector
or NF-κB RelA p65 overexpressing vector (purchased
from Origene Technologies, Rockville, MD; Cat #
RC220780) using FuGENE 6 transfection reagent (Roche,
Indianapolis, IN) following manufacturer’s instructions. All
experiments were performed and verified using at least
three biological replicates.
Acridine Orange staining for autophagy detection
Cell staining with Acridine orange (10 mg/ml in water,
A8097, Sigma Chemical Co) was performed according to
published procedures [9], adding at a final concentration
of 1 mg/ml for a period of 15 min. Bafilomycin A1 (Sigma
Chemical Co.) was dissolved in DMSO and added to the
cells 45 min before addition of acridine orange. Photo-
graphs were obtained with a fluorescence microscope
and percent of staining was determined by harvesting
cells by trypsinization and measuring with a FACSCali-
bur from (Becton Dickinson) using CellQuest software.
All experiments were performed and verified using at
least three biological replicates.
Results and Discussion
Helenalin Inhibits Cell Proliferation and Clonogenic
Survival in cancer cells
To examine the effect of helenalin on cell proliferation
and clonogenic survival, human ovarian cancer A2780
cells were treated with helenalin and effects on cellproliferation and survival was determined using phase
contrast microscopy, crystal violet staining and MTT
assays. Phase contrast micrographs of A2780 cells trea-
ted with increasing concentrations of helenalin of 0.5,
1.0 and 2uM for 24 h showed changes in cell number
and morphology. Morphologic signs of apoptosis included
changes such as membrane blebbing and apoptotic body
formation (Figure 1A). To measure the amount of cell
survival after helenalin exposure, A2780 cells were cul-
tured in the presence of increasing doses of helenalin
(serial dilution for drug concentration ranging from
10uM to 0.001uM) for 24 h and cell survival was deter-
mined using the MTT assay. As shown in Figure 1B, in-
creasing concentrations of helenalin reduced the
percentage of cell survival in a dose dependent manner.
To further investigate the growth suppression effect of
helenalin, we performed in vitro clonogenic assays.
Figure 1C shows the effects of helenalin on the clono-
genic potential of the control (DMSO) and helenalin-
treated A2780 cells. Helenalin reduced clonogenicity of
A2780 cells in a dose-dependent manner, where 2uM of
helenalin completely suppressed clonogenic growth.
Induction of G1 Phase Arrest and cell death by Helenalin
To identify the mechanism of helenalin-induced cell
proliferation inhibition and cell death, we examined the
effects of helenalin on cell cycle distribution by flow
cytometry. As shown in Figure 2A, cells in sub-G1 phase
increased in a helenalin dose dependent manner, analo-
gous with the earlier observation that helenalin inhibited
cell proliferation (Figure 1A). As much as 25 % of cells
in sub-G1 were observed in A2780 cells treated with
2uM helenalin (Figure 2B). To rule out that our findings
were cell line specific, we replicated our experiments in
MCF-7 breast adenocarcinoma cancer cell line and RKO
colon carcinoma cancer cell lines. As shown in Add-
itional file 1: Figure S1 A and C, increase in sub-G1 levels
were observed in these additional cancer cell lines, with
the RKO cell line exhibiting greater sensitivity to helena-
lin whilst MCF-7 cells were comparatively less sensitive.
As demonstrated previously for the A2780 cancer cell
line (Figure 1B), helenalin also reduced the percentage
of cell survival in a dose dependent manner in both the
MCF-7 and RKO cancer cell lines (Additional file 1:
Figure S1 B and D). As sub-G1 levels are an indicative
measurement of cell death [10,11], we examined
whether the fraction of cells in sub-G1 after helenalin
treatment was attributable to cells undergoing apop-
tosis. We measured apoptotic cell death by staining
with FITC-Annexin V and Propidium Iodide and per-
formed flow cytometry to analyze sub fractions of
cells undergoing apoptosis or necrosis. As revealed in
Figure 2C, partial increase in apoptotic cells was
observed after helenalin treatment when compared to
DMSO 0.5uM Hele
1uM Hele 2uM Hele
A B
C
Figure 1 Helenalin induces cytotoxicity in A2780 human ovarian cancer cell line Phase contrast micrographs of A2780 cells treated
with increasing concentrations of helenalin of 0.5, 1.0 and 2uM for 24 h. Changes in cell number and morphology were observed when
compared to DMSO control. (B) Percent of viable cells after treatment with increasing concentrations of helenalin (serial dilution for drug
concentration ranging from 10uM to 0.001uM) using the MTT assay. (C) Clonogenic survival assay. A2780 cells were treated with increasing
concentrations of helenalin and then incubated for 2 weeks. The cells were stained with crystal violet for 16 h. Representative dishes are shown.
All results represent data from three independent experiments.
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undergo cell death via apoptosis in addition to other
cell death mechanisms. In addition to the dose
dependent effects of helenalin observed, we performed
additional experiments to investigate the effects on
A2780 cells exposed to helenalin at varying treatment
times. Flow cytometry assays performed on cells har-
vested after different exposure times demonstrate an in-
crease in sub-G1 levels with increasing exposure to
helenalin (Figure 3A). As much as 35 % of cells are in
sub-G1 24 h post treatment with helenalin (Figure 3B).
Helenalin induces cell death via caspase cleavage and
induction of autophagy
To further investigate the mechanistic action of cell
death induced by helenalin, we performed western blot
analysis to detect proteins that have been shown to be
involved in both the intrinsic and extrinsic apoptosis
pathways. Cells treated with increasing concentrationsof helenalin were lysed and subjected to western blot
analysis for cleaved caspases 3 and 9 and also for
cleaved PARP. After 24 h of treatment, the levels of
cleaved caspases increased with increasing concentra-
tions of helenalin (Figure 4A). Using a dose of 2uM
helenalin, it was observed that levels of cleaved caspase
3, 9 and PARP were detected at the outset of 8 h post
treatment with subsequent increase in cleavage with
protracted treatment times (Figure 4B). To substantiate
the prerequisite of caspase cleavage as a determinant
for helenalin induced cell death, we employed the use
of the pan caspase inhibitor, Z-VAD-fmk to block cas-
pase cleavage during helenalin treatment and deter-
mined the levels of sub-G1cells by flow cytometry.
Addition of Z-VAD-fmk to cells prior to helenalin
treatment suppressed caspase 3, 9 and PARP cleavage
(Figure 4C) and levels of sub-G1 cells measured by
flow cytometry showed comparable levels to those of
control treated cells versus to those of cells treated
Figure 2 Helenalin induces cell cycle arrest in G1 phase and modulates apoptosis in a dose-dependent manner. (A) 1.85 × 105 cells/ml
were seeded onto 6-well plates and incubated for 24 h. Various concentrations of helenalin were added to the culture medium and incubated
for an additional 24 h. Cells were then harvested and analyzed by flow cytometry. The cell cycle phase distribution was determined using
CellQuest software. (B) Percent of cells in Sub-G1 after drug treatment representing three independent experiments. (C) Measurement of
apoptotic cell death by staining with FITC-Annexin V and Propidium Iodide. Lower right hand quadrant for each dose treatment represents
percent of apoptosis, while upper right hand quadrant represents early necrotic cells. (D) Percent of cells that are either apoptotic, necrotic or
total cell death as measured by staining cells with FITC-Annexin V and Propidium Iodide. Percentages are the average of three independent
biological replicates.
Lim et al. BMC Complementary and Alternative Medicine 2012, 12:93 Page 5 of 12
http://www.biomedcentral.com/1472-6882/12/93with helenalin alone (Figure 4D). Quantitative measure-
ments of cells in sub-G1 were reduced from levels of
~25 % in helenalin alone treated cells to less than 2 %
with helenalin in combination with Z-VAD-fmk
(Figure 4E). We subsequently investigated the intrinsic
cell death pathway by assessing the protein levels of
Bcl-2, Bax and Bid in lysates from cells treated with
different concentrations of helenalin. As shown in
Figure 5A, no appreciable differences in protein expres-
sion were observed suggesting that helenalin induced
cell death was not attributable to activation of the Bcl-
2, Bax and Bid. Interestingly, as shown in Figure 4,
helenalin activated caspase 9, strongly suggesting hele-
nalin induces intrinsic apoptotic cell death. We next
investigated the levels of Atg12 and LC3-B, both bio-
markers indicative of autophagy cell death. Asdemonstrated in Figure 5B, there was a dose dependent
increase in protein levels of Atg12 and LC3-B with in-
creasing concentrations of helenalin. Our findings are in
contrast to recently published data where there was no
increase of LC3-B detected in Jurkat cells treated with
helenalin [12]. The authors of this manuscript can only
speculate to the differences in observations as cell line
specific. To verify that cells were indeed undergoing
autophagy, cells were treated with varying concentra-
tions of helenalin and stained with Acridine Orange so-
lution to detect and measure acidic vesicular organelle
(AVO) formation. As shown in Figure 5C, vital staining
of cells with acridine orange showed the accumulation
of AVO in the cytoplasm of cells exposed to increasing
concentrations of helenalin. This was inhibited by
addition of bafilomycin A1 (200 nM), an H+ATPase
Figure 3 Helenalin induces cell cycle arrest in G1 phase and modulates apoptosis in a time-dependent manner. (A) 1.85 × 105 cells/ml
were seeded onto 6-well plates and incubated for 24 h. 2uM of helenalin was added to the culture medium and incubated for 4,8,12 and 24 h.
Cells were harvested and analyzed by flow cytometry. The cell cycle phase distribution was determined using CellQuest software. Figures
represent data from three independent experiments. (B) Percent of cells in Sub-G1 after the indicated timepoints representing three biological
experiments.
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was quantitated in cells treated with helenalin or/and
Balifomycin A1, by trypsinizing and harvesting cells for
FACS analysis. Approximately 80 % of cells treated
with 2uM helenalin for 24 h were positive for AVO
staining and these levels were completely abrogated by
the addition of Bafilomycin A1 (Figure 5D).Inhibition of Atg12 and LC3-B expression
reduces caspase cleavage and cell death induced
by Helenalin
To investigate the significance of Atg12 and LC3-B in
cells undergoing helenalin induced autophagy, we de-
pleted Atg12 and LC3-B in A2780 cells using siRNA-
mediated knockdown. Post siRNA transfection and
Cleaved Caspase 3
Cleaved PARP
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Figure 4 Helenalin activates caspase cleavage. A2750 cells were treated with increasing concentrations of helenalin for 24 h (A) or with 2uM
helenalin for the indicated timepoints (B), following which cells were harvested and cell lysates prepared and subjected to immunoblot analysis
for cleaved PARP, caspase 3 and 9. Actin was used as a loading control.A2750 cells were subjected to caspase inhibitor, Z-VAD-fmk treatment two
hours before addition of 2uM helenalin for 24 h, following which the cells were lysed and subjected to (C) immunoblot analysis for cleaved
caspases and PARP or (D) harvested and analyzed for cell cycle flow distribution using FACS analysis. (E) Percent of cells in Sub-G1 in DMSO,
helenalin or Z-VAD-fmk plus helenalin treatment. All figures represent data from three independent experiments.
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protein levels for both Atg12 and LC3-B when com-
pared to cells treated with a non targeting control
siRNA (Figure 6A and B). Intriguing, upon helenalin
treatment, the protein levels of cleaved caspases were
reduced in cells depleted of Atg12 and LC3-B as com-
pared to cells treated with helenalin and transfected
with a control non-targeting siRNA (Figure 6A and B).
In addition, flow cytometry analysis performed in cells
treated with Atg12 or LC3-B showed a decrease in
sub-G1 levels when compared to cells treated with a
non-targeting siRNA (Figure 6C and D). This result is
consistent with previous findings where decrease in
LC3-B was associated with reduced autophagy and
cells treated with LC3-B or Beclin 1 siRNA inhibited
caspase-3/8 activation [13]. In the context of helenalin
induced cell death, this result implies that both Atg12
and LC3-B modulate caspase cleavage essential for
autophagy.NF-κB p65 inhibition by Helenalin is essential for caspase
cleavage and induction of autophagy
To ascertain the mechanism by which helenalin induces
Atg12 and LC3-B expression, we concerted our efforts
in understanding the role of the transcription factor
NF-κB p65 in helenalin induced autophagy. Previous
reports have demonstrated helenalin’s role in anti-
cancer and anti-inflammatory effects by inhibiting NF-
κB and telomerase activity and impairing protein and
DNA synthesis [6]. In addition, helenalin interacts with
RelA to inhibit DNA binding to its cognate response
elements and by inhibiting activation of the transcrip-
tion factor NF-κB [7]. Blockade of NF-κB/p65 binding
to DNA with helenalin correlated with induction of
cell death in a dose-dependent manner [14]. Numerous
reports have demonstrated NF-κB p65 to play a role
in autophagy induced cell death [13,15], however the
function in which helenalin participated in autophagy
was unknown. Amalgamating this information, we
DMSO 24hr 1uM Hele 24hr
2uM Hele 24hr 200nM Bafilomycin,
2uM Hele 24hr
0.5uM Hele 24hr



























Figure 5 Helenalin induces autophagy cell death. A2750 cells were treated with increasing concentrations of helenalin for 24 h, following
which cells were harvested and cell lysates prepared and subjected to immunoblot analysis for (A) BCL2, BAX and Bid or (B) Atg12 and LC3-B.
Actin was used as the loading control. A2750 cells were treated with DMSO, 0.5uM, 1uM, 2uM helenalin or pretreated with 200nM bafilomycin A1
for 45 min before treatment with 2uM helenalin for 24 h. Following which, cells were stained with Acridine Orange Solution and photographed
using a florescence microscope (positive AVO staining in red) (C) or (D) trypsinized and harvested for FACS analysis to quantitate levels of cell
staining representing autophagy. Figures represent data from three independent experiments.
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nalin induced autophagy cell death. As shown in
Figure 7A, helenalin reduced the expression of NF-κB
p65 in a dose dependent manner. Exogenous over-
expression of NF-κB p65 reduced the levels of cleaved
caspase 3, 9 and LC3-B in cells treated with helenalin
(Figure 7B) with subsequent reduction of sub-G1 levels
(Figure 7C), while siRNA mediated transcriptional knock-
down of NF-κB p65 increased cleaved caspase 3 and 9
but not LC3-B after helenalin treatment (Figure 7D)
with consequent increase in sub-G1 levels in cells
(Figure 7E). No differences in LC3-B levels were
observed after siRNA knockdown of NF-κB, since after
helenalin treatment, NF-κB levels are reduced by the
drug itself. This result was recapitulated in MCF-7 and
RKO cells with analogous outcomes (data not shown).Conclusions
Helenalin induces autophagy cell death via suppression
of NF-κB p65
Pharmacologically active natural compounds such as
those from marine and terrestrial plants and animals
represent a promising resource for novel anticancer drugs.
There are several prominent examples from the past
proving the success of natural products and derivatives
exhibiting anticancer activity. This includes the Vinca
alkaloids from Catharanthus roseus, the terpene pacli-
taxel from Taxus brevifolia, the DNA topoisomerase I
inhibitor camptothecin from Camptotheca acuminata,
and the semisynthetic derivatives etoposide and tenipo-
side of the lignan podophyllotoxin from Podophyllum
peltatum. Natural products alone or synthetics devel-
oped based on knowledge gained from natural products














































   















   












Tukey's Multiple Comparison Test Significant? P < 0.05? 
siRNA Neg DMSO vs siRNA Neg Hele Yes
siRNA Neg DMSO vs siRNA Atg12 DMSO No 
siRNA Neg DMSO vs siRNA Atg12 Hele 
siRNA Neg Hele vs siRNA Atg12 DMSO 
siRNA Neg Hele vs siRNA Atg12 Hele 
siRNA Atg12 DMSO vs siRNA Atg12 Hele 
Tukey's Multiple Comparison Test Significant? P < 0.05?  S
siRNA Neg DMSO vs siRNA LC3II DMSO
siRNA Neg DMSO vs siRNA LC3II Hele 
siRNA Neg Hele vs siRNA LC3II DMSO
siRNA Neg Hele vs siRNA LC3II Hele 
siRNA LC3II DMSO vs siRNA LC3II Hele 
Figure 6 Helenalin induced caspase cleavage and autophagy is dependent on Atg12 and LC3-B. A2780 cells were transfected with either
non-targeting siRNA (siRNA Neg) or Atg12 or LC3-B-specific siRNA for 24 h and then treated with either DMSO or helenalin for 24 h. Cells were
harvested and (A and B) cell lysates were subjected to immunoblot analysis for Atg12, LC3-B, cleaved PARP, caspase 3 or 9 or (C and D) analyzed
for cell cycle phase distribution by FACS. All experiments were performed in biological triplicates. Actin was used as the loading control. One way
ANOVA was performed between control and treatment groups, and significant differences were observed between the groups as indicated in
Figure 6C and D. Categories significant after multiple comparison are marked as “Yes”.(p-value <0.05; Tukey’s multiple comparison test).
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proved between 1980s and 2002 [16].
Herbal medicine has been applied in the clinic for
thousands of years in Asian countries such as China,
Japan and Korea [17]. However, because of its compli-
cated chemical composition and lack of concrete evi-
dence of its biological activity, herbal medicine is still
not widely accepted by the Western medical community
[18]. Unlike modern drugs in the form of a single active
compound, herbal medicine is usually prepared from
aqueous extracts of a few herbs and contains hundreds
or even thousands of different compounds [19].However, only a few compounds are responsible for the
pharmacological effects [19]. Furthermore, the bioactive
components are generally present at low level. Some
components are useless or even toxic. Thus, systematic
characterization of active chemicals in herbal medicinal
preparations and their mechanisms of action are import-
ant for providing the rationale for their efficacy and for
transforming herbal medicine practices into evidence-
based medicine.
Helenalin, an extracted component of Arnica Montana
and Arnica chamissonis is a sesquiterpene lactone with
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Tukey's Multiple Comparison Test Significant? P < 0.05? 
siRNA Neg DMSO vs siRNA Neg Hele
siRNA Neg DMSO vs RelA p65 O/N DMSO
siRNA Neg DMSO vs RelA p65 O/N Hele
siRNA Neg Hele vs RelA p65 O/N DMSO Yes
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siRNA Neg DMSO vs siRNA RelA p65 DMSO 
siRNA Neg DMSO vs siRNA RelA p65 Hele 
siRNA Neg Hele vs siRNA RelA p65 DMSO 
siRNA Neg Hele vs siRNA RelA p65 Hele 
siRNA RelA p65 DMSO vs siRNA RelA p65 Hele
Figure 7 Repression of NF-κB p65 expression by Helenalin is necessary for caspase cleavage and autophagy. (A) A2750 cells were
treated with increasing concentrations of helenalin for 24 h, following which cells were harvested and cell lysates prepared and subjected to
immunoblot analysis for NF-κB. (B) A2780 cells were transfected with an empty vector or vector over-expressing RelA p65. 24 h post transfection,
cells were treated with DMSO or 2uM helenalin for 24 h,and harvested for immunoblot analysis for cleaved caspase 3 and 9, LC3-B or NF-κB p65
or (C) trypsined and analyzed by FACS for precent of cells in sub-G1. One way ANOVA was performed for sub-G1 cells between control (DMSO)
and treatment groups, and significant differences were observed between the groups as indicated in Figure 7C. Categories significant after
multiple comparison are marked as “Yes”.(p-value <0.05; Tukey’s multiple comparison test). (D) A2780 cells were transfected either with a non-
targeting siRNA (siRNA Neg) or siRNA targeting RelA p65. 24 h post transfection, cells were treated with DMSO or 2uM helenalin for 24 h and
harvested for immunoblot analysis for cleaved caspase 3 and 9, LC3-B or NF-κB p65 or (E) trypsined and analyzed by FACS for percent of cells in
sub-G1. One way ANOVA was performed for sub-G1 cells between control (DMSO) and treatment groups, and significant differences were
observed between the groups as indicated in Figure 7E. Categories significant after multiple comparison are marked as “Yes”.(p-value <0.05;
Tukey’s multiple comparison test). All experiments were performed in biological triplicates and actin was used as a loading control for
immunoblot analysis.
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http://www.biomedcentral.com/1472-6882/12/93The use of helenalin has been demonstrated to reduce
the growth of Staphylococcus aureus and Plasmodium
falciparum [21] [22].In addition, previous studies have
implicated helenalin to selectively inhibit the transcrip-
tion factor NF-κB [7] and human telomerase activity [5],
suggesting an underlying molecular mechanism for its
antitumor activity.
Our ensuing findings derived from experiments per-
formed in cancer cells treated with helenalin consistently
resulted in an increase in cell death via apoptosis andautophagy. The increased sensitivity to cell death when
exposed to helenalin was associated with increased levels
of caspase cleavage. Indeed, when caspase cleavage was
blocked using a specific inhibitor, cell death was consid-
erably reduced. Given that several anticancer agents
exert their effects by triggering autophagy, we postulated
whether helenalin’s action in triggering cell death was
through the activation of autophagy. Treatment with
helenalin resulted in an increase in defined autophagy
markers, which when transcriptionally silenced using
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http://www.biomedcentral.com/1472-6882/12/93siRNA resulted in decreased cell death. Interestingly,
transcriptionally silencing Atg12 and LC3-B, both essen-
tial for induction of autophagy cell death also resulted in
a decrease of caspase activity. This result suggests that
caspase activation is dependent on the expression of
Atg12 and LC3-B. These observations are in agreement
with previous studies where a decrease in LC3-B levels
was associated with reduced autophagy and cells treated
with LC3-B or Beclin 1 siRNA inhibited caspase-3/8 ac-
tivation [13]. To further validate our findings, we per-
formed Acridine Orange staining assays to measure acidic
vesicular organelle (AVO) formation, a key indicator of
autophagy initiation. AVO formation increased with in-
creasing concentrations of helenalin and was suppressed
with the use of bafilomycin A1, a highly potent and se-
lective inhibitor of vacuolar H+−ATPases used in pre-
venting the re-acidification of synaptic vesicles leading
to the autophagy process [23-26].
We next examined whether helenalin’s mechanism of
action was through the transcription factor NF-κB. Pre-
vious reports had revealed helenalin as a potent inhibitor
of NF-κB [27] and that its binds with RelA disrupting its
transcriptional activity [28]. In addition, NF-κB is a key
regulator of several biological processes, including prolif-
eration, differentiation, apoptosis and autophagy [29,30].
NF-κB has been demonstrated to play an essential role
after heat shock treatment by modulating autophagy by
a mechanism to increase cell survival, possibly through
the elimination of irreversibly damaged proteins [31-33].
With this regard, we observe that upon helenalin treat-
ment, the level of NF-κB p65 (RelA) was reduced. Re-
introducing RelA exogenously via an over-expression
construct we observed that caspase activation was re-
duced together with the levels of autophagy markers,
resulting in decreased cell death. Conversely, transcrip-
tionally silencing NF-κB p65 had the outcome of in-
creasing caspase cleavage, autophagy markers and cell
death. These results strongly advocate the reliance of
NF-κB p65 for helenalin induced autophagy cell death.
We speculate helenalin downregulates NF-κB p65 ex-
pression via ubiquitination-mediated degradation. Previ-
ous reports have shown that tumor necrosis factor-α
(TNFα) polyubiquitinatates RelA at the lysine 195 resi-
due which is critical for degradation of p65 [34]. The
precise mechanism of p65 degradation needs to be fur-
ther investigated.
In summary, we have shown that helenalin induces cell
death via a mechanism involving the repression of NF-κB
p65 expression resulting in an increase of autophagy
markers and caspase activation. This provokes the clinic-
ally relevant question as to helenalin’s use as a thera-
peutic intervention in patients with aberrant activation
of NF-κB. Clinically, acute myeloid leukemia (AML) is
an aggressive cancer with median survival rates of 2 to3 months, and inhibition of NF-κB is considered one of
the therapeutic strategies for treatment [30,35-39]. Onco-
genic addiction of activated NF-κB could be inhibited
with the use of helenalin, and as such could favorably be
used in a therapeutic setting to augment tumor sensitiv-
ity to conventional chemotherapeutic drugs. Further
work is necessary before helenalin can be considered as
a lead compound and a treatment strategy. Specificity,
toxicology, pharmacokinetics and metabolism needs to
be investigated and studied further before it is intro-
duced into the market.
Additional files
Additional file 1: Figure S1. Helenalin induces cell cycle arrest in G1
phase and modulates cell survival in a dose-dependent manner. (A)
MCF-7 cells were seeded onto 6-well plates and incubated for 24 h.
Various concentrations of helenalin were added to the culture medium
and incubated for an additional 24 h. Cells were then harvested and
analyzed by flow cytometry. The cell cycle phase distribution was
determined using CellQuest software.(B) Percent of viable MCF-7 cells
after treatment with increasing concentrations of helenalin (serial dilution
for drug concentration ranging from 10uM to 0.001uM) using the MTT
assay. (C) RKO cells were seeded onto 6-well plates and incubated for
24 h. Various concentrations of helenalin were added to the culture
medium and incubated for an additional 24 h. Cells were then harvested
and analyzed by flow cytometry. The cell cycle phase distribution was
determined using CellQuest software.(D) Percent of viable RKO cells after
treatment with increasing concentrations of helenalin (serial dilution for
drug concentration ranging from 10uM to 0.001uM) using the MTT assay.
All experiments were performed in biological triplicates.
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